CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03850964
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-10-28T01:07:04.623425+00:00
Published At: 2026-10-27T00:00:00+00:00
Record Updated At: 2026-10-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hereditary Hemorrhagic Telangiectasia", "Epistaxis", "Anemia", "Nosebleed", "HHT"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-10-27"
protocolSection.identificationModule.nctId: "NCT03850964"
protocolSection.identificationModule.officialTitle: "A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.